Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed...
Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed...
Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding...
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...